ED50 against cervical cancer (CaSki, SiHa, and HeLa cells) ranging from 0.5 to 5.1 μM. In HeLa cells vorinostat was able to downregulate several proteins, such as ALDR, HSPB1, IF5A1, and PGAM1. Also in HeLa cells, a reduction in the mRNA levels of HPV18 E6 and E7 and transcription of both genes were reported, suggesting that vorinostat is a useful drug for cervical cancer. This evidence concerns the gene HSPB1 and cervical carcinoma.